Lorundrostat significantly lowers BP in treatment-resistant hypertension

Lorundrostat, an aldosterone synthase inhibitor, effectively and safely lowered BP in adults with uncontrolled and treatment-resistant hypertension, supporting the use of the novel drug as a treatment option for this population.

Study details: The phase 3 Launch-HTN study (NCT06153693) evaluated lorundrostat in 1,083 adults with uncontrolled or treatment-resistant hypertension. Participants (50% female, 29% Black, and 63% with obesity) were on 2 to 5 antihypertensive medications and underwent a 3-week standardized regimen before randomization to placebo, lorundrostat 50 mg daily, or lorundrostat 50 mg with potential escalation to 100 mg. Primary endpoint was change in 24-hour systolic BP at 12 weeks.

Results: In the pooled 50 mg lorundrostat group (n=808), systolic BP dropped by 16.9 mm Hg (95% confidence interval [CI], -19 to -14.9) at 6 weeks vs. 7.9 mm Hg (95% CI, -11.5 to -4.2) with placebo—a significant difference of −9.1 mm Hg (p < .001). Adverse events such as hyperkalemia, hyponatremia, and reduced kidney function were more common with lorundrostat but led to few treatment discontinuations (<1%).

Source:

Saxena M, et al; Launch-HTN Investigators. (2025, June 30). JAMA. Lorundrostat in Participants With Uncontrolled Hypertension and Treatment-Resistant Hypertension: The Launch-HTN Randomized Clinical Trial. https://pubmed.ncbi.nlm.nih.gov/40587141/